Cytarabine, known as cytosine arabinoside, is a chemotherapy medication used to treat acute myeloid leukemia, acute lymphocytic leukemia, chronic myelogenous leukemia, and non-Hodgkin's lymphoma.
| FactSnippet No. 736,617 |
12 Facts About Cytarabine
2.
Cytarabine is in the antimetabolite and nucleoside analog families of medication.
| FactSnippet No. 736,618 |
3.
Cytarabine was patented in 1960 and approved for medical use in 1969.
| FactSnippet No. 736,619 |
4.
Cytarabine is mainly used in the treatment of acute myeloid leukaemia, acute lymphocytic leukaemia and in lymphomas, where it is the backbone of induction chemotherapy.
| FactSnippet No. 736,620 |
5.
Cytarabine possesses antiviral activity, and it has been used for the treatment of generalised herpesvirus infection.
| FactSnippet No. 736,621 |
6.
Cytarabine is used in the study of the nervous system to control the proliferation of glial cells in cultures, the amount of glial cells having an important impact on neurons.
| FactSnippet No. 736,622 |
7.
Cytarabine is the first of a series of cancer drugs that altered the sugar component of nucleosides.
| FactSnippet No. 736,623 |
8.
Cytarabine is often given by continuous intravenous infusion, which follows a biphasic elimination – initial fast clearance rate followed by a slower rate of the analog.
| FactSnippet No. 736,624 |
9.
Cytarabine is rapidly deaminated by cytidine deaminase in the serum into the inactive uracil derivative.
| FactSnippet No. 736,625 |
10.
Cytarabine-5´-monophosphate is deaminated by deoxycytidylate deaminase, leading to the inactive uridine-5´-monophosphate analog.
| FactSnippet No. 736,626 |
11.
Cytarabine is able to inhibit herpesvirus and vaccinia virus replication in cells during tissue culture.
| FactSnippet No. 736,627 |
12.
Cytarabine was first synthesized in 1959 by Richard Walwick, Walden Roberts, and Charles Dekker at the University of California, Berkeley.
| FactSnippet No. 736,628 |